Physician profile
Mary E Trujillo
NPI 1669407698
$4,645.40
in general payments reported to CMS, 2019-2025
27 companies · $658 in 2025
The $658 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,679 · 2022: $733 · 2023: $945 · 2024: $630 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.20 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $1,951.40 | 2021-2023 | |
| Abbvie INC. | $482.10 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $295.12 | 2022-2024 | |
| Genentech USA, INC. | $258.45 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Csl Behring | $233.13 | 2022-2025 | Hizentra, Privigen |
| Acadia Pharmaceuticals INC | $183.52 | 2022-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $152.22 | 2023-2025 | Ingrezza, Ongentys |
| Acorda Therapeutics, INC | $149.94 | 2022-2023 | Inbrija |
| Revance Therapeutics, INC. | $140.01 | 2025 | Daxxify |
| Eisai INC. | $104.58 | 2023-2025 | |
| Neurelis, INC. | $86.72 | 2021-2024 | Valtoco |
| Biogen, INC. | $75.57 | 2022-2025 | Vumerity |
| Lilly USA, LLC | $71.47 | 2022-2023 | Emgality, Reyvow, Amyvid |
| Sk Life Science, INC. | $62.60 | 2022-2023 | |
| Amgen INC. | $61.69 | 2021-2024 | Uplizna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $48.58 | 2024-2025 | Rexulti |
| Allergan, INC. | $44.67 | 2022 | |
| Lundbeck LLC | $40.28 | 2024-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $36.85 | 2025 | |
| Amneal Pharmaceuticals LLC | $28.60 | 2022-2024 | Rytary |
| Alexion Pharmaceuticals, INC. | $27.01 | 2024 | Ultomiris |
| Ucb, INC. | $24.08 | 2025 | Rystiggo |
| Sunovion Pharmaceuticals INC. | $24.03 | 2022 | |
| Argenx US, INC. | $18.74 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Banner Life Sciences, LLC | $18.13 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.39 | 2022 | |
| Digestive Care, INC. | $12.52 | 2025 | Pertzye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Trujillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.